Boule Diagnostics AB (CHIX:BOULs)
kr 26.3 (0%) Market Cap: 147.57 Mil Enterprise Value: 351.07 Mil PE Ratio: 0 PB Ratio: 0.86 GF Score: 47/100

Q4 2024 Boule Diagnostics AB Earnings Call Transcript

Feb 11, 2025 / 09:00 AM GMT
Release Date Price: kr26.3

Key Points

Positve
  • Boule Diagnostics AB (OSTO:BOUL) reported a significant improvement in adjusted operating profit, increasing by 85.7% to 19.5 million SEK.
  • The company executed its third and most comprehensive restructuring round, resulting in annualized savings of approximately 18 million SEK.
  • A new supply chain function was established, integrating purchasing, planning, and order management to optimize processes and enhance customer service.
  • The licensed instrument manufacturing site in India went live as scheduled, contributing to the first instrument license revenue in the quarter.
  • Boule Diagnostics AB (OSTO:BOUL) entered a multi-year exclusive distribution agreement with Vital Scientific, expected to add approximately 20 million SEK to US revenue with a good margin profile.
Negative
  • Overall sales were negatively impacted by a lower average selling price on instruments.
  • Consumable sales were negatively affected by the transition to a licensed manufacturing model in India.
  • Higher restructuring costs adversely impacted cash flow.
  • Sales in Southeast Asia struggled due to competitive pressure from Chinese manufacturers and local policies favoring local products.
  • The company faced challenges in Africa with delayed payments blocking new orders.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BOUL.ST - Boule Diagnostics AB
Q4 2024 Boule Diagnostics AB Earnings Call
Feb 11, 2025 / 09:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning everybody and welcome to the 4th quarter's earnings hall for Goog Diagnostics. I'm Jorge Lambe, CFO for Goo Diagnostics. With me, I have our CEO Ton Nilsen, and after our presentations, we will open up for questions. Please also feel free to type questions in the chat field and along the presentation.

With that, I'm handing over to our CEO.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Torin.

Thank you, Holger, and good morning to everybody on the call.

Let's begin by taking a look at the Q4 highlights.

Overall, it was a stable
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot